Skip to content Skip to footer
Cytonics Corporation
Cytonics Corporation
Cytonics Corporation
Close

#63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD Approach

Investor Relations, Our Story, Science CornerJanuary 6, 2026640Views0Likes0Comments
You may have seen the recent headlines regarding a breakthrough in "anti-aging injections" for cartilage regeneration, published in Science (Singla et al., 2025). Led by Stanford Medicine, this research identifies the inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as a novel pathway to restore regenerative capacity in chondrocytes (the cartilage-secreting cells in joints). While the media is…

Read More

#52 🥊 Positioned to Win: Why Cytonics Stands Out in the 2025 Biotech Landscape

Investor RelationsJune 9, 20251KViews0Likes0Comments
Cytonics aims to address osteoarthritis, impacting over 500 million globally, with its innovative CYT-108 therapy. Positioned strategically in capital markets, the company targets Phase 2-ready investments. With strong intellectual property and funding strategies, Cytonics is well-prepared for M&A opportunities, benefiting from current biotech trends and investor interests.

Read More

#51 🥋 When Injury Meets Innovation: Rener Gracie’s Journey to Cytonics

Investor Relations, Our StoryJune 1, 20251KViews0Likes0Comments
Rener Gracie, a renowned jiu-jitsu master, faced a career-threatening knee injury but found hope through APIC™ therapy during recovery. Impressed by its life-changing results, he became an investor and advocate for CYT-108, a groundbreaking biologic therapy for osteoarthritis, emphasizing grassroots medicine and challenging traditional pharmaceutical methods.

Read More

#50🔊Listen To Our CEO Describe Our Science In 40 Seconds

Joey Bose, Investor Relations, Our StoryMay 27, 2025690Views0Likes0Comments
Cytonics has released a video featuring CEO Joey Bose, explaining how their therapy CYT-108 challenges Big Pharma by targeting osteoarthritis’s root causes, rather than just symptoms. The video discusses past successes with APIC, the science behind their approach, and future strategies. Viewers are encouraged to support the company as potential shareholders.

Read More

#47 🪙Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development

Investor Relations, Our StoryMarch 25, 2025654Views0Likes0Comments
Cytonics is seeking $24 million to fund a Phase 2 Clinical Study for CYT-108, its innovative osteoarthritis therapy. This fundraising effort, in partnership with StartEngine, utilizes Regulation A+, allowing unaccredited investors to participate. CYT-108 offers unique protease inhibition benefits and builds on the success of its predecessor, the APIC system.

Read More

#46 📢 Critical Patent Issuance Protecting Lead Drug Candidate

Investor Relations, Our StoryMarch 8, 2025646Views0Likes0Comments
Cytonics Corporation has received US Patent No. US 12,195,521 B2 for its engineered A2M variant, CYT-108. This patent enhances its competitive position by expanding therapeutic applications and securing exclusivity for two decades. It strengthens barriers to entry, increases licensing opportunities, and supports funding initiatives for future product development.

Read More

Marketing by Katapult Marketing
© 2026 Cytonics Corporation – All rights reserved

Get fresh updates
Subscribe

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 30 East 23rd Street, 2nd Floor, NY, NY 10010, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA’s BrokerCheck. DealMaker Securities LLC does not make investment recommendations. DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer. DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor’s documentation for this investment. DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing. DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself. Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

This website may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

Receive News

Download Exclusive Investor Presentation & Stay Updated

Name(Required)
Privacy(Required)